Dr Adam Januszewski· @AdamJanuszewski · X·· 4 小时前评分70
正文 · 原文
🚨 #ESMO26 Another promising ADC in 2L EGFRm NSCLC!
Ph3 HER3 ADC ruzaltatug rezetecan vs chemo:
📈 PFS 8.3 vs 5.4m (HR 0.47)
📈 ORR 60% vs 34%
📈 OS HR 0.70 (immature)
⚠️ ILD 2.4%
Competitive ADC landscape! More mature OS & global data needed.
8 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA13按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.org来源：Dr Adam Januszewski · x.com